Cargando…
Cancer worry among BRCA1/2 pathogenic variant carriers choosing surgery to prevent tubal/ovarian cancer: course over time and associated factors
OBJECTIVE: High cancer risks, as applicable to BRCA1 and BRCA2 pathogenic variant (PV) carriers, can induce significant cancer concerns. We examined the degree of cancer worry and the course of this worry among BRCA1/2-PV carriers undergoing surgery to prevent ovarian cancer, and identified factors...
Autores principales: | van Bommel, Majke H. D., Steenbeek, Miranda P., IntHout, Joanna, Hermens, Rosella P. M. G., Hoogerbrugge, Nicoline, Harmsen, Marline G., van Doorn, Helena C., Mourits, Marian J. E., van Beurden, Marc, Zweemer, Ronald P., Gaarenstroom, Katja N., Slangen, Brigitte F. M., Brood-van Zanten, Monique M. A., Vos, M. Caroline, Piek, Jurgen M., van Lonkhuijzen, Luc R. C. W., Apperloo, Mirjam J. A., Coppus, Sjors F. P. J., Prins, Judith B., Custers, José A. E., de Hullu, Joanne A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857097/ https://www.ncbi.nlm.nih.gov/pubmed/34997316 http://dx.doi.org/10.1007/s00520-021-06726-4 |
Ejemplares similares
-
Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis
por: van Bommel, Majke H D, et al.
Publicado: (2022) -
Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study
por: Harmsen, Marline G., et al.
Publicado: (2015) -
A patient decision aid for risk‐reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing
por: Harmsen, Marline G., et al.
Publicado: (2017) -
TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol
por: Steenbeek, Miranda P, et al.
Publicado: (2023) -
Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
por: Zaaijer, Leendert H, et al.
Publicado: (2016)